Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in ...

Bertrand Y. Tuan, MD, hematologist/oncologist at Pacific Hematology Oncology Associates and California Pacific Medical Center ...

Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, ...

The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...

Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care "We look forward to begin treating CKD anemia patients on dialysis with ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...

Study finds annual healthcare costs per patient are significantly higher than previously described– HHT costs are higher than other ...

If you’re able to get a closer look at your poop, black BMs due to iron will usually have a greenish tint, says Ashkan ...

Keros Therapeutics has inked an agreement potentially worth more than $1 billion with Japan's Takeda Pharmaceutical aimed at advancing Keros' elritercept drug candidate ... stage development for the ...

There comes a moment in every child’s life when they begin to discover that, although their parents may seem to have all the ...